JMP Securities Maintains Market Outperform on Macrogenics, Lowers Price Target to $38
JMP Securities analyst Silvan Tuerkcan maintains Macrogenics (NASDAQ:MGNX) with a Market Outperform and lowers the price target from $39 to $38.
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
JMP Securities Initiates Coverage On Macrogenics with Market Outperform Rating, Announces Price Target of $39
JMP Securities analyst Silvan Tuerkcan initiates coverage on Macrogenics (NASDAQ:MGNX) with a Market Outperform rating and announces Price Target of $39.
Last Week’s Notable Insider Buys Included Evergy, Frontier Communications And More
Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain.
The week's most notable insider buys were at an REIT, a telecommunications company, a biotech and a utility.
Owners with more than a 10% stake have been bolstering those stakes.
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Why Are I-Mab Shares Trading Higher On Tuesday?
The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mab’s (NASDAQ:IMAB) IND application to initiate a…
Notable Insider Buys Of The Past Week Include Designer Brands, MacroGenics And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs.
The week's most notable insider buys were at two biotechs, a chemicals company and a shoemaker.
Some insiders were making return trips to the buy window.
